MagneGas Corporation (NASDAQ:MNGA), a leading energy and technology company that counts among its inventions a patented process that converts liquid waste into a hydrogen-based fuel, on 10 June announced that it has filed a patent improvement application to the design of their electrodes. MagneGas Corporation (NASDAQ:MNGA) weekly performance is 5.88%. On last trading day company shares ended up $1.62. Analysts mean target price for the company is $0.95. MagneGas Corporation (NASDAQ:MNGA) distance from 50-day simple moving average (SMA50) is 15.86%.
On June 11, 2014, Vringo, Inc. (NASDAQ:VRNG) held its 2014 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, 65,017,008 votes were present in person or represented by proxy, which represented 75.15% of the total outstanding eligible votes as of the record date of April 21, 2014. Vringo, Inc. (NASDAQ:VRNG) shares advanced 4.42% in last trading session and ended the day on $3.54. VRNG return on assets is -61.50%.Vringo, Inc. (NASDAQ:VRNG) quarterly performance is -1.67%.
EnteroMedics, Inc. (NASDAQ:ETRM) stock declined Friday after the FDA posted a document reviewing its Maestro rechargeable system. Comments might suggest concern about limited data.
EnteroMedics Inc. (NASDAQ:ETRM) shares moved down -1.22% in last trading session and was closed at $1.62, while trading in range of $1.50 – $1.73. EnteroMedics Inc. (NASDAQ:ETRM) year to date (YTD) performance is -20.59%.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) chief executive officer Mark Baker commented on the FDA Advisory Committee meeting held this week, in a conference call on June 13, at 8:30 a.m. Eastern Time. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) ended the last trading day at $4.14. Company weekly volatility is calculated as 10.84% and price to cash ratio as 3.06.Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) showed a positive weekly performance of 19.65%.
ISIS Pharmaceuticals Inc. (NASDAQ:ISIS) CEO Stanley T. Crooke sold 11,000 shares of the company’s stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $33.46, for a total value of $368,060.00. Following the completion of the sale, the chief executive officer now directly owns 6,941 shares in the company, valued at approximately $232,246. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) net profit margin is -69.60% and weekly performance is 10.63%. On last trading day company shares ended up $33.63. Analysts mean target price for the company is $43.56. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) distance from 50-day simple moving average (SMA50) is 10.79%.
Leave a Reply